A pilot project showed that clinics using the InheRET tool were able to gather more complete family history information from patients, which is important for further cancer risk evaluation.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
After a study showed that patients who received guidance from Perthera's tumor board lived longer than those who didn't, the company wants to make its technology more accessible.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
Currently available under a soft launch, the tool can provide information about the prevalence of cancer risk mutations based on patients' demographics.
![[node:title] photo [node:title] photo](https://www.genomeweb.com/sites/default/files/styles/detail/public/images/bio/charlotte_125_170.jpg?itok=8ijvG6wV)
